Statements (61)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:agent |
gptkb:battle
|
| gptkbp:approves |
gptkb:1956
gptkb:FDA |
| gptkbp:aroma |
5% solution
20% solution 25% solution |
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
gptkb:Osmitrol
|
| gptkbp:class |
gptkb:beer
|
| gptkbp:clinical_trial |
Phase IV
cardiac surgery neurosurgery urological surgery ophthalmic surgery trauma management intensive care unit management |
| gptkbp:contraindication |
pulmonary edema
active intracranial bleeding severe renal disease |
| gptkbp:dissolved |
soluble in water
|
| gptkbp:dosage_form |
gptkb:software_framework
|
| gptkbp:duration |
1 to 3 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
sterile solution
|
| https://www.w3.org/2000/01/rdf-schema#label |
Mannitol for Injection
|
| gptkbp:indication |
gptkb:sneaker
cerebral edema prevention of acute kidney injury |
| gptkbp:ingredients |
C6 H14 O6
|
| gptkbp:interacts_with |
may affect lithium levels
may enhance nephrotoxicity of certain drugs may interact with other diuretics |
| gptkbp:is_used_for |
promoting diuresis
reducing intracranial pressure treating oliguric renal failure |
| gptkbp:level |
5.0 to 7.0
|
| gptkbp:lifespan |
1.5 hours
|
| gptkbp:manager |
intravenous
IV infusion |
| gptkbp:manufacturer |
various pharmaceutical companies
|
| gptkbp:metabolism |
not metabolized
|
| gptkbp:packaging |
vials
|
| gptkbp:premiered_on |
immediate
|
| gptkbp:safety_features |
Category C
|
| gptkbp:side_effect |
headache
nausea electrolyte imbalance fever dehydration chills fluid overload hypotension thrombophlebitis |
| gptkbp:size |
100 m L
250 m L 50 m L |
| gptkbp:storage |
room temperature
|
| gptkbp:weight |
182.17 g/mol
|
| gptkbp:bfsParent |
gptkb:Mannitol
|
| gptkbp:bfsLayer |
5
|